RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Pablo Vivas to Antineoplastic Agents

This is a "connection" page, showing publications Pablo Vivas has written about Antineoplastic Agents.
Connection Strength

0.964
  1. Reyes-Gonz?lez JM, Armaiz-Pe?a GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarr?a-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mej?a PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
    View in: PubMed
    Score: 0.306
  2. Echevarr?a-Vargas IM, Valiyeva F, Vivas-Mej?a PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 2014; 9(5):e97094.
    View in: PubMed
    Score: 0.282
  3. Vivas-Mej?a PE, Cox O, Gonz?lez FA. Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides. Mol Cell Biochem. 1998 Jan; 178(1-2):203-12.
    View in: PubMed
    Score: 0.091
  4. Vivas-Mej?a PE, Rodr?guez-Cab?n JL, D?az-Vel?zquez M, Hern?ndez-P?rez MG, Cox O, Gonzalez FA. DNA binding-independent anti-proliferative action of benzazolo[3,2-alpha]quinolinium DNA intercalators. Mol Cell Biochem. 1997 Dec; 177(1-2):69-77.
    View in: PubMed
    Score: 0.090
  5. B?ez-Vega PM, Echevarr?a Vargas IM, Valiyeva F, Encarnaci?n-Rosado J, Roman A, Flores J, Marcos-Mart?nez MJ, Vivas-Mej?a PE. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget. 2016 Jun 14; 7(24):36321-36337.
    View in: PubMed
    Score: 0.081
  6. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.
    View in: PubMed
    Score: 0.073
  7. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.016
  8. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.012
  9. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support